65 related articles for article (PubMed ID: 1702181)
1. [Study on the mechanism of tumor regression by adoptive immunochemotherapy in mice].
Miyake N
Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1524-33. PubMed ID: 1702181
[TBL] [Abstract][Full Text] [Related]
2. In vivo analysis of the 'bystander effect': a cytokine cascade.
Ramesh R; Marrogi AJ; Munshi A; Abboud CN; Freeman SM
Exp Hematol; 1996 Jun; 24(7):829-38. PubMed ID: 8647234
[TBL] [Abstract][Full Text] [Related]
3. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model.
Lefor AT; Fabian DF
J Surg Res; 1998 Feb; 75(1):49-53. PubMed ID: 9614856
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
6. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
Kurt RA; Park JA; Panelli MC; Schluter SF; Marchalonis JJ; Carolus B; Akporiaye ET
J Immunol; 1995 Apr; 154(8):3969-74. PubMed ID: 7706735
[TBL] [Abstract][Full Text] [Related]
7. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
8. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
9. Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor.
Takiguchi K; Nakamoto T; Inagawa H; Kohchi C; Nishizawa T; Nagasue N; Soma G
Anticancer Res; 2004; 24(3a):1823-8. PubMed ID: 15274362
[TBL] [Abstract][Full Text] [Related]
10. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
11. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus type 1 alters transcript levels of tumor necrosis factor-alpha and interleukin-6 in retinal glial cells.
Drescher KM; Whittum-Hudson JA
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2302-12. PubMed ID: 8843914
[TBL] [Abstract][Full Text] [Related]
13. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
Li B; Ding J; Larson A; Song S
In Vivo; 1999; 13(5):433-8. PubMed ID: 10654199
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice.
Hashemi SM; Hassan ZM; Soudi S; Ghazanfari T; Kheirandish M; Shahabi S
Int Immunopharmacol; 2007 Jul; 7(7):920-7. PubMed ID: 17499194
[TBL] [Abstract][Full Text] [Related]
15. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Stoppacciaro A; Forni G; Colombo MP
Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
[TBL] [Abstract][Full Text] [Related]
18. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
19. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
Yang X; Chu Y; Wang Y; Zhang R; Xiong S
J Leukoc Biol; 2006 Dec; 80(6):1434-44. PubMed ID: 16980511
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
